MTNB - Matinas BioPharma Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.8100
-0.0200 (-2.41%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.8300
Open0.8300
Bid0.7100 x 2900
Ask0.8312 x 800
Day's Range0.8100 - 0.8400
52 Week Range0.3240 - 1.5000
Volume451,013
Avg. Volume894,214
Market Cap115.823M
Beta (3Y Monthly)3.13
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire15 days ago

    Matinas BioPharma to Present at the 9th Annual LD Micro Invitational

    Matinas BioPharma is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of MAT9001 for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal (“LNC”) platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines. The Company is actively pursuing the development of MAT9001 with the support of a world-class team of clinical key opinion leaders and regulatory consultants. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels.

  • GlobeNewswire21 days ago

    Matinas BioPharma Announces Publication of MAT2203 Preclinical Cryptococcal Meningitis Data in the American Society for Microbiology Journal, mBio

    – Efficacy of oral delivery of amphotericin B (MAT2203) demonstrated comparable efficacy to IV amphotericin, with similar survival of animals and reduction in fungal burden – –.

  • GlobeNewswire28 days ago

    Matinas BioPharma Announces Abstract Accepted for Presentation at ASM Microbe 2019

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that its abstract of preclinical data of MAT2501, an orally administered, lipid nano-crystal (“LNC”) formulation of the broad spectrum aminoglycoside antibiotic agent amikacin, has been selected for two presentations at the ASM Microbe 2019 scientific meeting being held June 20–24 in San Francisco, CA.

  • GlobeNewswirelast month

    Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates

    Formulations of select antivirals will be developed using Matinas’ LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Promising formulations will be tested in in vivo preclinical studies to identify a lead LNC-antiviral formulation to take forward in development.

  • GlobeNewswirelast month

    Matinas BioPharma Provides Corporate Update and Reports First Quarter 2019 Financial Results

    BEDMINSTER, N.J., May 14, 2019 -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced its financial results for the.

  • GlobeNewswirelast month

    Matinas BioPharma to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 14, 2019

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 14, 2019 at 8:30 a.m. ET to discuss operational and financial results for the quarter ended March 31, 2019 as well as provide a corporate update. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal (“LNC”) platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines.

  • GlobeNewswire2 months ago

    Matinas BioPharma to Ring NYSE Opening Bell® on May 6, 2019

    BEDMINSTER, N.J., May 02, 2019 -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has been invited to.

  • GlobeNewswire2 months ago

    Matinas BioPharma Selected to Present at the BioNJ Ninth Annual BioPartnering Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Theresa Matkovits, Ph.D., Chief Development Officer of the Company, was selected to present a corporate overview and host one-on-one meetings with leading industry executives at BioNJ’s Ninth Annual BioPartnering Conference on Wednesday, May 8, 2019 during the afternoon session being held 2:00 PM – 3:00 PM ET. As part of her presentation, Dr. Matkovits will provide a corporate update and will discuss the Company’s differentiated LNC drug delivery platform. Matinas’ LNC platform technology offers an intracellular drug delivery solution with potential advantages for a range of therapeutics, including small molecules, nucleic acid polymers, proteins, peptides, vaccines, as well as the targeted delivery of gene editing technologies.  Dr. Matkovits will also provide an overview of the Company’s lead anti-infective pipeline candidate, MAT2203.

  • GlobeNewswire3 months ago

    Matinas BioPharma Reports 2018 Financial Results and Provides Corporate Update

    –  Key focus on advancing the development of MAT9001, a potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar prescription-only.

  • GlobeNewswire3 months ago

    Matinas BioPharma to Announce Full-Year 2018 Operational and Financial Results on April 2, 2019

    The call will be led by Jerome D. Jabbour, Chief Executive Officer of Matinas. Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's anticipated capital and liquidity needs, strategic focus and the future development of its product candidates, including MAT9001 and MAT2203, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions.

  • Business Wire3 months ago

    Matinas BioPharma to Present at the 31st Annual ROTH Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present at the 31st Annual ROTH Conference on Tuesday, March 19 at 2:30 PM PT in Dana Point, CA. As part of his presentation, Mr. Jabbour will provide a corporate update and will discuss MAT9001, the Company’s proprietary prescription-only omega-3 fatty acid-based composition. Matinas is developing MAT9001 for therapeutic applications in the cardiovascular and metabolic fields with the support of a world-class team of clinical key opinion leaders and regulatory consultants.

  • Business Wire3 months ago

    Matinas BioPharma Announces Pricing of Public Offering of Common Stock

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten registered public offering of 27,272,727 shares of its common stock, offered at a price to the public of $1.10 per share for expected gross proceeds of $30.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Matinas BioPharma has granted the underwriters a 30-day option to purchase up to an additional 4,090,909 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Matinas BioPharma.

  • Business Wire3 months ago

    Matinas BioPharma Announces Proposed Public Offering of Common Stock

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering are to be sold by Matinas BioPharma. In connection with the offering, Matinas BioPharma intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.

  • GlobeNewswire4 months ago

    Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has appointed a prominent cardiovascular medical and clinical development expert, James (“Terry”) J. Ferguson, M.D., FACC, FAHA, as its Chief Medical Officer.

  • ACCESSWIRE5 months ago

    Biotech Breaking Out

    HENDERSON, NV / ACCESSWIRE / January 16, 2019 / Since hitting its lows on Dec. 26, biotech has soared more than 20 percent as of Friday, and was posting its best start to a year since 2012. Here are a ...

  • GlobeNewswire5 months ago

    Matinas BioPharma Announces a Research Evaluation with Top Global Pharma Company Based on Its Proprietary Drug Delivery Platform

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced they have signed an agreement with an undisclosed top global pharmaceutical company aimed to evaluate synergistic effects of Matinas’ lipid-nano-crystal (“LNC”) platform delivery technology with their partner’s nucleic acid polymer technology. Formulations will be developed using Matinas’ LNC delivery technology which enables the development of a wide range of difficult-to-deliver molecules. For competitive reasons, the agreement stipulates certain confidential provisions, including the pharmaceutical company’s identity, the therapeutic molecule(s), the intended targets and the financial terms of the agreement.

  • GlobeNewswire5 months ago

    Matinas BioPharma Appoints Keith A. Kucinski, CPA, MBA as Chief Financial Officer

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has appointed Keith A. Kucinski, CPA, MBA as Chief Financial Officer. Mr. Kucinski brings to Matinas over 20 years of diversified and broad finance expertise with demonstrated leadership and success in financial and strategic planning, accessing the capital markets and mergers and acquisitions across the healthcare and business consulting industries. Jerome D. Jabbour, Chief Executive Officer, commented, “As we look to drive our Company forward in 2019 and maximize the value of our products and platform technology, we have taken deliberate steps to bolster our management team over the past few months.

  • GlobeNewswire6 months ago

    Matinas BioPharma to Present at Biotech Showcase 2019

    As part of his presentation, Mr. Jabbour will provide a corporate update and will discuss MAT9001, the Company’s proprietary prescription-only omega-3 fatty acid-based composition, comprised of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), a highly potent but less prevalent omega-3 fatty acid with very unique properties, and other omega-3 fatty acids. The Company recently announced the formation of a Scientific Advisory Board to guide clinical development strategy of its potential best-in-class prescription-only omega-3, MAT9001, and appointed three internationally renowned experts as its first members. Matinas is developing MAT9001 for therapeutic applications in the cardiovascular and metabolic fields with the support of a world-class team of clinical key opinion leaders and regulatory consultants.

  • GlobeNewswire6 months ago

    Matinas BioPharma Appoints Harold E. Bays, M.D. to its Cardiovascular Health Scientific Advisory Board

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced the appointment of Harold E. Bays, M.D. to its Scientific Advisory Board (SAB). Dr. Bays is Board Certified in Endocrinology and Internal Medicine, Diplomate of the American Board of Clinical Lipidology, and Diplomate of the American Board of Obesity Medicine. Dr. Bays joins the Company’s recently appointed SAB members, Christie M. Ballantyne, M.D., John J.P. Kastelein, M.D., Ph.D., FESC, and Kevin C. Maki, Ph.D., now representing four of the world’s leading lipid specialists and cardiovascular health experts.

  • GlobeNewswire6 months ago

    Matinas BioPharma Assembles World Class Scientific Advisory Board to Guide Clinical Development Strategy of Potential Best-in-Class Prescription-Only Omega-3, MAT9001

    BEDMINSTER, N.J., Dec. 06, 2018 -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has established   a.

  • GlobeNewswire7 months ago

    Detailed Research: Economic Perspectives on Sunstone Hotel Investors, Acadia Realty Trust, Matinas Biopharma, Compass Diversified, Aspen Insurance, and Superior Drilling Products — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE7 months ago

    4 Stocks To Watch As Healthcare Technology Industry Is Expecting Rapid Growth Through 2025

    CORAL GABLES, FL / ACCESSWIRE / November 13, 2018 / The U.S. patient engagement solutions market size is anticipated to reach $12.3 billion by 2025, expanding at a CAGR of 19.5% over the forecast period according to reports from Research And Markets*. With the volatility in today's market, many investors have turned to biotechnology and healthcare stocks as a safe haven from the broader market activity. Furthermore, the new age of technology and aging population unable to frequently visit a physical doctor's office has created a larger demand for technology intervention within the healthcare industry.

  • ACCESSWIRE7 months ago

    3 Healthcare Stocks Pushing The Boundaries Of Innovation: Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Matinas BioPharma Holdings, Inovalon Holdings

    The Smart Medical Devices Market, for example, is expected to witness healthy growth (no pun intended) according to a report by Market Research Future*. Biotech companies have found that this demand is unwavering and are working toward catering to it by increasing investments toward the development of more efficient methods of self-administration of drugs and diagnosis. Sector trends in healthcare technology and new treatments for rare diseases have sparked more interest in sector stocks.

  • GlobeNewswire7 months ago

    Matinas BioPharma Reports Third Quarter 2018 Financial Results and Provides Corporate Update

    –  Key focus on advancing the development of MAT9001, a proprietary, potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar.